Harvard Bioscience (NASDAQ:HBIO) Given New $7.50 Price Target at Benchmark

Posted by Brian Himes on Aug 12th, 2026

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) had its price objective upped by research analysts at Benchmark from $6.00 to $7.50 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “speculative buy” rating on the medical instruments supplier’s stock. Benchmark’s price objective points to a potential upside of 22.35% from the company’s previous close.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Harvard Bioscience in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $6.75.

Check Out Our Latest Research Report on HBIO

Harvard Bioscience Price Performance

Shares of NASDAQ:HBIO opened at $6.13 on Wednesday. The company has a 50-day moving average price of $6.15 and a two-hundred day moving average price of $5.82. Harvard Bioscience has a twelve month low of $3.75 and a twelve month high of $9.40. The company has a quick ratio of 1.06, a current ratio of 1.99 and a debt-to-equity ratio of 3.60. The firm has a market capitalization of $27.65 million, a PE ratio of -2.82 and a beta of 1.49.

Harvard Bioscience (NASDAQ:HBIO – Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.07. The company had revenue of $22.73 million during the quarter, compared to the consensus estimate of $21.45 million. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%.

Hedge Funds Weigh In On Harvard Bioscience

Large investors have recently added to or reduced their stakes in the business. Weber Capital Management LLC ADV purchased a new position in shares of Harvard Bioscience during the fourth quarter valued at approximately $2,140,000. Corsair Capital Management L.P. lifted its stake in Harvard Bioscience by 1,008.7% in the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock worth $741,000 after acquiring an additional 1,008,692 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new stake in Harvard Bioscience in the fourth quarter valued at $401,000. Meros Investment Management LP boosted its holdings in Harvard Bioscience by 32.6% in the fourth quarter. Meros Investment Management LP now owns 1,217,628 shares of the medical instruments supplier’s stock valued at $814,000 after acquiring an additional 299,369 shares in the last quarter. Finally, Two Sigma Investments LP increased its position in Harvard Bioscience by 139.7% during the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 276,372 shares during the period. Hedge funds and other institutional investors own 80.87% of the company’s stock.

Harvard Bioscience News Roundup

Here are the key news stories impacting Harvard Bioscience this week:

Positive Sentiment: Second-quarter revenue increased 11% year over year to $22.7 million, above the $21.45 million analyst consensus. Adjusted EBITDA rose to $1.7 million from $1.5 million, and adjusted EPS of negative $0.14 beat expectations of negative $0.21. Harvard Bioscience Announces Second Quarter 2026 Financial Results
Positive Sentiment: Management raised full-year 2026 revenue guidance to $89.1 million-$90.9 million, versus the prior consensus of $88.6 million, implying 3%-5% growth. It also expects full-year adjusted EBITDA growth of 6%-10%. Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance
Positive Sentiment: The company highlighted Project Viking, a strategic transformation aimed at strengthening its focus on translational science. Recent insider activity was also supportive, with executives and directors making purchases and no reported sales during the past six months. Harvard Bioscience Advances Transformation with Project Viking Launch
Neutral Sentiment: Third-quarter revenue guidance of $21.0 million-$22.6 million brackets the $21.9 million consensus, suggesting limited near-term upside despite the stronger full-year forecast.
Negative Sentiment: GAAP net loss widened to $2.9 million, or approximately $0.14 per share, from $2.3 million a year earlier. Gross margin was 55.6%, while management expects product and geographic mix, including CMT and China, to move future gross margin toward 57%-59%. Harvard Bioscience targets 2026 revenue growth
Negative Sentiment: The company’s continuing losses, negative profitability metrics and highly leveraged balance sheet may be tempering enthusiasm over the earnings beat. The mixed institutional activity—eight investors added shares while 40 reduced positions—also signals limited conviction.

About Harvard Bioscience

(Get Free Report)

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.